Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT03531684 Completed - Alzheimer Disease Clinical Trials

Efficacy and Safety of MMFS in Early AD

Start date: March 20, 2018
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the safety and efficacy of MMFS for improving cognition and global function in patients with probable Early Alzheimer's disease.

NCT ID: NCT03522129 Completed - Alzheimer Disease Clinical Trials

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

Start date: May 30, 2018
Phase: Phase 1
Study type: Interventional

This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.

NCT ID: NCT03520998 Completed - Alzheimer Disease Clinical Trials

A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

Start date: April 16, 2018
Phase: Phase 2
Study type: Interventional

This study is evaluating the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild to moderate Alzheimer's disease.

NCT ID: NCT03518073 Completed - Clinical trials for Alzheimer Disease (AD)

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

Start date: April 30, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

NCT ID: NCT03510572 Completed - Parkinson Disease Clinical Trials

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain

Start date: June 4, 2018
Phase: Early Phase 1
Study type: Interventional

The overall goal of this imaging trial is to evaluate [18F]PI-2620, a tau targeted positron emission computed tomography radioligand, in individuals with tauopathies and healthy volunteers (HV).

NCT ID: NCT03508024 Completed - Lewy Body Disease Clinical Trials

Patients With Alzheimer's Disease or Related Youth Disease

PARMAAJJ
Start date: January 5, 2018
Phase:
Study type: Observational

This study aims to determine factors related to diagnosis delay for patients with young onset dementia (first symptoms before 60 years old) who live in North of France.

NCT ID: NCT03507790 Completed - Clinical trials for Mild to Moderate Alzheimer's Disease

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Start date: October 10, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

NCT ID: NCT03503669 Completed - Clinical trials for Mild Cognitive Impairment

Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this pilot study will be to test whether Kundalini yoga (KY) and Kirtan Kriya (KK) yogic meditation is superior to Memory Enhancement Training (MET) for improving cognitive functioning, health (including cardiovascular factors), and mood in women with high AD risk.

NCT ID: NCT03493282 Completed - Alzheimer Disease Clinical Trials

Effect of CT1812 Treatment on Brain Synaptic Density

Start date: March 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.

NCT ID: NCT03489044 Completed - Alzheimer Disease Clinical Trials

An Investigation of Levetiracetam in Alzheimer's Disease

ILiAD
Start date: October 28, 2018
Phase: Phase 2
Study type: Interventional

The study proposed aims to evaluate the effect of Levetiracetam in patients with Alzheimer's disease (AD) in a Phase 2 Clinical Trial. Levetiracetam is an established anti-epileptic medication that has been approved by NICE (UK) as a first line treatment for focal epilepsy. Levetiracetam is now generic and acts, as all anti-epileptic medications do, by stabilising neuronal networks. However, Levetiracetam appears unique amongst the anti-epileptic medications in being able to stabilise aberrant neuronal networks in Alzheimer's disease. In both animal models of AD and in patients with mild cognitive impairment, Levetiracetam can offer benefit to cognition. The investigators therefore aim to test whether Levetiracetam, through stabilisation of neuronal networks, may offer benefit to cognition in patients with AD.